Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes

Fan, Zhicheng; Zhang, Qiaoxin; Chen, Huanzhu; He, Ping; Li, Yazhen; Si, Mengya; Jiao, Xiaoyang

doi:10.1016/j.micpath.2017.10.003

Cited by 18 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extracellular vesicles could be useful markers to predict the risk of hepatitis B virus reactivation and detection of early fibrosis for hepatitis B and C. Results of studies on that topic are summarised in Table S3 [104][105][106][107][108] and the supplementary text [104][105][106][107][108][109][110] for hepatitis B, and Table S4 82,84,105,[111][112][113][114][115][116][117][118][119][120][121] and the supplementary text 82,84,105,[111][112][113][114][115][116][117][118][119][120][121][122] for hepatitis C.…”

Section: Hepatitis B and C Virus Infectionsmentioning

confidence: 99%

Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view

Thietart

Rautou

2020

Journal of Hepatology

128

View full text Add to dashboard Cite

Extracellular vesicles are membrane-bound vesicles containing proteins, lipids, RNAs and microRNAs. They can originate from both healthy and stressed cells, and provide a snapshot of the cell of origin in physiological and pathological circumstances. Various processes that may give rise to the release of extracellular vesicles occur in liver diseases, including hepatocyte apoptosis, hepatic stellate cell activation, liver innate immune system activation, systemic inflammation, and organelle dysfunction (mitochondrial dysfunction and endoplasmic reticulum stress). Numerous studies have therefore investigated the potential role of extracellular vesicles as biomarkers in liver diseases. This review provides an overview of the methods that can be used to measure extracellular vesicle concentrations in clinical settings, ranging from plasma preparation to extracellular vesicle measurement techniques, as well as looking at the challenges of using extracellular vesicles as biomarkers. We also provide a comprehensive review of studies that test extracellular vesicles as diagnostic, severity and prognostic biomarkers in various liver diseases, including non-alcoholic and alcoholic steatohepatitis, viral hepatitis B and C infections, cirrhosis, primary liver cancers, primary sclerosing cholangitis and acute liver failure. In particular, extracellular vesicles could be useful tools to evaluate activity and fibrosis in non-alcoholic fatty liver disease, predict risk of hepatitis B virus reactivation, predict complications and mortality in cirrhosis, detect early hepatocellular carcinoma, detect malignant transformation in primary sclerosing cholangitis and predict outcomes in acute liver failure. While most studies draw on data derived from pilot studies, which still require clinical validation, some extracellular vesicle subpopulations have already been evaluated in solid prospective studies.

show abstract

Section: Hepatitis B and C Virus Infectionsmentioning

confidence: 99%

Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view

Thietart

Rautou

2020

Journal of Hepatology

128

View full text Add to dashboard Cite

show abstract

“…HCV genotyping is a major cause of DAA treatment failure [ 23 ]. DAAs inhibit various parts of HCV protein including NS3/4A, NS5A, and NS5B protein.…”

Section: Discussionmentioning

confidence: 99%

“…Liver-specific miRNA miR-122 or interference of the RNA interference pathway associated with miRNA biogenesis resulted in the inhibition of HCV replication [ 24 ]. Circulating miRNAs (cmiRNAs) in the plasma or serum have been assessed for evaluations of the therapeutic response and antiviral effects in patient with hepatitis C, since cmiRNAs are protected from RNase and stabilized even in the serum [ 23 , 25 , 26 ]. Therefore, toward the goal of reducing the virological failure rate of DAA treatment, we examined targetable miRNAs during HCV elimination by OBV/PTV/r.…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir

Morishita¹,

Yoneyama²,

Iwama³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection causes sustained inflammation and fibrosis. Several oral direct-acting antivirals (DAAs) including ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) were recently developed for HCV elimination. The combination of DAAs brought a higher sustained viral response (SVR) rate to anti-HCV therapy compared to interferon (IFN)-based regimens. However, 5% of hepatitis C patients who undergo DAA therapy still suffer from a sustained HCV infection. MicroRNA (miRNA) is essentially interfering, endogenous noncoding RNA that has been investigated as a new biomarker for the response to DAA in hepatitis C patients. Here we used a miRNA array and real-time polymerase chain reaction (PCR) to determine the targetable miRNA before and 12 weeks after OBV/PTV/r treatment for refractory hepatitis C. We used replicon cells, in which genotype 1b type HCV is stably transfected in Huh7 cells, to determine whether miRNA can inhibit HCV replication. Among 2,555 miRNAs, three were significantly up-regulated and eight miRNAs were down-regulated in serum 12 weeks after OBV/PTV/r treatment. An unsupervised hierarchical clustering analysis, using Pearson's correlation, showed that the miRNA profiles between before and 12 weeks after OBV/PTV/r treatment were clustered separately. At 12 weeks after OBV/PTV, miR-636 was targeted among the eight down-regulated miRNAs, and the expression level of circulating miR-636 was significantly diminished. The amount of HCV-RNA was significantly diminished 48 hours after miR-636 inhibitor transfection in HCV replicon cells. In conclusion, miR-636 might be one of the essential targetable molecules in HCV patients who undergo DAA therapy and still suffer from a sustained HCV infection.

show abstract

“…For example, 30-50% of individuals infected with hepatitis C virus (HCV) will not respond effectively to antiviral treatment (Cavalcante and Lyra, 2015). A liver-enriched miRNA, miR-122, has been shown to predict the efficacy of HCV therapy better than traditional circulating biomarkers, including alanine aminotransferase (ALT), albumin, and HCV RNA (Fan et al, 2017). Furthermore, circulating miR-122 was found to decrease alongside detectable HCV RNA during antiviral therapy, reflecting successful HCV treatment (Koberle et al, 2013).…”

Section: Advantages Of Mirna Biomarkers Iv: Personalized Medicinementioning

confidence: 99%

MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing

et al. 2020

View full text Add to dashboard Cite

In the pursuit of improved diagnostic tests for infectious diseases, several classes of molecules have been scrutinized as prospective biomarkers. Small (18-22 nucleotide), non-coding RNA transcripts called microRNAs (miRNAs) have emerged as promising candidates with extensive diagnostic potential, due to their role in numerous diseases, previously established methods for quantitation and their stability within biofluids. Despite efforts to identify, characterize and apply miRNA signatures as diagnostic markers in a range of non-infectious diseases, their application in infectious disease has advanced relatively slowly. Here, we outline the benefits that miRNA biomarkers offer to the diagnosis, management, and treatment of infectious diseases. Investigation of these novel biomarkers could advance the use of personalized medicine in infectious disease treatment, which raises important considerations for validating their use as diagnostic or prognostic markers. Finally, we discuss new and emerging miRNA detection platforms, with a focus on rapid, point-of-care testing, to evaluate the benefits and obstacles of miRNA biomarkers for infectious disease.

show abstract

Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes

Cited by 18 publications

References 34 publications

Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view

Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir

MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing

Contact Info

Product

Resources

About